Finance News

AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026

First Commercial Deployment of FDA-Cleared AI-Guided TMS Navigation System, Expanded FDA Pathway for NRX-101, and Growing Commercial Infrastructure Highlight Accelerating Momentum for NRx Pharmaceuticals (N A S D A Q: NRXP)

Business